AngioDynamics APEX-AV Trial Results Assessing AlphaVac F18 System For Treatment Of Pulmonary Embolism Presented At SCAI 2024 Scientific Sessions
Portfolio Pulse from Benzinga Newsdesk
AngioDynamics presented results from the APEX-AV trial of its AlphaVac F18 System for treating pulmonary embolism at SCAI 2024. The data showed the system is safe for patients with acute intermediate-risk PE, significantly improving right ventricular function and reducing clot burden.
May 06, 2024 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics' successful trial results for the AlphaVac F18 System could lead to increased adoption and sales, positively impacting its financial performance.
The positive trial results presented at a significant scientific session indicate a strong potential for market acceptance and increased sales of the AlphaVac F18 System. This could lead to improved revenue streams for AngioDynamics, making the news highly relevant and important for investors. The confidence in this analysis is based on the direct impact of product efficacy on company performance in the healthcare sector.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90